Therapeutic Potential of Ascorbic Acid in the Management of Alzheimer's
Disease: An Update

Semwal, Bhupesh Chander; Singh, Bhoopendra; Murti, Yogesh; Singh, Sonia

doi:10.2174/1389201024666230804102617

Cited by 2 publications

(1 citation statement)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown promising outcomes by administering EGCG and AA, leading to enhanced therapeutic advantages in treating AD. 11,12 Single-molecule-targeting approaches could lead to unintended effects on nontargeted sites. This could restrict the application of single-molecule targeting, especially in complex clinical conditions.…”

Section: Introductionmentioning

confidence: 99%

Development of Epigallocatechin and Ascorbic Acid Dual Delivery Transferosomes for Managing Alzheimer’s Disease: In Vitro and in Vivo Studies

Mishra,

Awasthi,

Mishra

et al. 2024

ACS Omega

View full text Add to dashboard Cite

and ascorbic acid (AA)-loaded transferosomes (TRANS) were developed for brain delivery. The investigation covered EGCG-TRANS, AA-TRANS, and EGCG-AA-TRANS formulations using the film hydration technique. We analyzed the formed transferosomes to confirm the presence of vesicles loaded with the respective drugs and their performance within a living organism. The sizes of the particles for EGCG-TRANS, AA-TRANS, and EGCG-AA-TRANS were measured correspondingly at 174.2 ± 1.80, 132.7 ± 12.22, and 184.31 ± 9.5 nm. The appearance of diffused rings in the scanning electron microscopic image suggests that the payload has a crystalline structure. The atomic force microscope image displayed minimal surface irregularities, potentially indicating the presence of a lipid layer on the surface. Hemolysis results indicated the safety of the vesicles. The results showed 10.23, 7.21, and 8.20% of hemolysis for EGCG-TRANS, AA-TRANS, and EGCG-AA-TRANS, respectively. In the case of EGCG-AA-TRANS, the release of EGCG was determined to be 61.65% ± 4.61 after 72 h when exposed to phosphate buffer saline (pH 7.4). In vivo studies show a good response against Alzheimer's disease (AD). EGCG-AA-TRANS (82.166%) exhibited a higher percentage of AChE inhibition in comparison to EGCG-TRANS (66.550%) and AA-TRANS (53.466%). Intranasal delivery of EGCG-AA-TRANS resulted in approximately a 5-fold enhancement in memory. Formulation allowed EGCG and AA to accumulate in various organs, including the brain. The results suggest that EGCG-AA-TRANS could be safe and effective for treating AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of Epigallocatechin and Ascorbic Acid Dual Delivery Transferosomes for Managing Alzheimer’s Disease: In Vitro and in Vivo Studies

Mishra,

Awasthi,

Mishra

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

Development of a method for the voltammetric determination of ascorbic acid on a palladium doped carbonaceous electrode

Çelik,

Üstündağ

2024

Nevşehir Bilim Ve Teknoloji Dergisi

View full text Add to dashboard Cite

Ascorbic acid (AA) is a vital antioxidant with critical roles in human health, including immune system support and protection against oxidative stress. Accurate and sensitive determination of AA is essential in clinical diagnostics, pharmaceutical analysis, and food quality control. In this study, a novel voltammetric method was developed using a glassy carbon (GC) electrode modified with palladium-doped carbonaceous material for AA detection. A mixture of equal amounts of raw coal tar pitch (r-CTP) and glass fiber (GF) was pyrolyzed in a high-temperature furnace at 1000°C for 1 h, with a heating rate of 10°C/min under a nitrogen atmosphere. The resulting carbonized material was ground using a planetary ball mill (Retsch, PM100), and palladium nanoparticles (PdNPs) were then doped onto the material via the sol-gel method. The obtained material is denoted Pd/CTP-GF. Pd/CTP-GF was characterized using scanning electron microscopy (SEM) and X-ray diffraction (XRD). The glassy carbon (GC) electrode modified with Pd/CTP-GF was characterized by cyclic voltammetry (CV). A method was developed for the determination of ascorbic acid using differential pulse voltammetry (DPV) on the Pd/CTP-GF modified GC electrode. The detection limit (S/N=3) of the developed method was determined to be 5 nM. The intraday and interday precision and accuracy of the method were also evaluated. In addition, the interference of dopamine, uric acid, and certain cations on ascorbic acid was investigated. In real sample applications, the developed method achieved a recovery of over 95% for ascorbic acid in orange juice samples. Keywords: Ascorbic acid; differential pulse voltammetry; palladium nanoparticle; carbonaceous electrode.

show abstract

Therapeutic Potential of Ascorbic Acid in the Management of Alzheimer's Disease: An Update

Cited by 2 publications

References 149 publications

Development of Epigallocatechin and Ascorbic Acid Dual Delivery Transferosomes for Managing Alzheimer’s Disease: In Vitro and in Vivo Studies

Development of Epigallocatechin and Ascorbic Acid Dual Delivery Transferosomes for Managing Alzheimer’s Disease: In Vitro and in Vivo Studies

Development of a method for the voltammetric determination of ascorbic acid on a palladium doped carbonaceous electrode

Contact Info

Product

Resources

About